摘要
背景:常染色体显性多囊性肾病(ADPKD)是临床上最常见的遗传性肾病。主要的临床表现是肾脏的双侧和渐进性囊肿形成,损害正常的肾实质,最终导致终末期肾病(ESRD)。ADPKD是一种异源性疾病,它是由编码多囊蛋白1(PC1)和- 2(PC2)的PKD1或PKD2基因的突变而产生的,因此涉及多个细胞信号通路。 方法:尽管致病基因和异常信号通路已经被研究了数十年,但是对这种疾病有效性的缺乏和更少的副作用的治疗仍然困扰着广大的临床医生。因此,目前对ADPKD的新治疗方法的开发是非常需要的。 总结:本综述将以ADPKD发病机制为中心,并将讨论基因转移作为该疾病的潜在治疗方法。新的治疗干预措施将为改善这种不治之症的预后,带来进一步的希望。
关键词: 异常信号通路,常染色体显性多囊性肾病,致病基因,基因治疗,肾病,转译医学
Current Gene Therapy
Title:Perspectives of Gene Therapies in Autosomal Dominant Polycystic Kidney Disease
Volume: 17 Issue: 1
关键词: 异常信号通路,常染色体显性多囊性肾病,致病基因,基因治疗,肾病,转译医学
摘要: Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease in the clinic. The predominant clinical manifestation is bilateral and progressive cysts formation in the kidneys, impairs normal renal parenchyma, and ultimately leads to endstage renal disease (ESRD). ADPKD is a heterogenic disease which is resulted from the mutations of PKD1 or PKD2 genes which encode polycystin-1 (PC1) and -2 (PC2), thereby multiple cell signaling pathways are involved.
Method: Although causative genes and aberrant signaling pathways have been investigated for decades, lack of effective and less side-effect treatment for the disease still perplex vast clinicians. Therefore, development of new therapeutic approaches for ADPKD is currently very much desired. Conclusion: This review will center on pathogenesis of ADPKD, and thereafter gene transfer will be discussed as potential treatment for the disease. New therapeutic interventions will bring further hope to improve prognosis of this incurable disease.Export Options
About this article
Cite this article as:
Perspectives of Gene Therapies in Autosomal Dominant Polycystic Kidney Disease, Current Gene Therapy 2017; 17 (1) . https://dx.doi.org/10.2174/1566523217666170510152808
DOI https://dx.doi.org/10.2174/1566523217666170510152808 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Voltage-Gated Sodium Channels for Treating Neuropathic and Inflammatory Pain
Current Pharmaceutical Biotechnology Male Pelvic Pain: Beyond Urology and Chronic Prostatitis
Current Rheumatology Reviews Treatment of Chronic Migraine with Intramuscular Pericranial Injections of Onabotulinumtoxin A
Recent Patents on CNS Drug Discovery (Discontinued) Neuro-Transmitters in the Central Nervous System & their Implication in Learning and Memory Processes
Current Medicinal Chemistry Anticoagulant Therapy During Pregnancy for Maternal and Fetal Acquired and Inherited Thrombophilia
Current Medicinal Chemistry Fragile X Syndrome and Autism: Common Developmental Pathways?
Current Pediatric Reviews Peptide-Derived Protease-Activated Receptor-1 (PAR-1) Antagonists
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Transforming Growth Factor β Signaling Perturbation in the Loeys-Dietz Syndrome
Current Medicinal Chemistry Nicotinic Receptors in Neurodegeneration
Current Neuropharmacology Post-stroke Depression Therapy: Where are we now?
Current Neurovascular Research Hyperuricaemia and Non-Alcoholic Fatty Liver Disease (NAFLD): A Relationship with Implications for Vascular Risk?
Current Vascular Pharmacology Von Hippel-Lindau Disease
Current Molecular Medicine Small Molecular Inhibitors Targeting Chromatin Regulating Proteins for Cancer
Current Protein & Peptide Science Premature Ovarian Failure (POF) Syndrome: Towards the Molecular Clinical Analysis of its Genetic Complexity
Current Medicinal Chemistry The Genetics of Small-Vessel Disease
Current Medicinal Chemistry Tuberculosis Therapeutics: Past Achievements, Present Road-Blocks and Future Perspectives
Letters in Drug Design & Discovery <i>In Silico</i> Docking Studies of Vascular Endothelial Growth Factor-A (VEGFA): Possible Implications in Chronic Myeloid Leukemia (CML) Therapy
Current Proteomics Incretins Yesterday, Pleiotropic Gastrointestinal Hormones Today:Glucagon-Like Peptide-1 (GLP-1) and Glucose-ependent Insulinotropic Polypeptide (GIP)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Mouse Models of Autoimmune Uveitis
Current Pharmaceutical Design Gene Therapy for Osteoinduction
Current Gene Therapy